(0.12%) 5 137.50 points
(0.08%) 38 472 points
(0.20%) 17 881 points
(-0.24%) $83.65
(1.66%) $1.955
(0.13%) $2 350.30
(0.48%) $27.67
(1.52%) $936.10
(-0.18%) $0.933
(-0.28%) $10.99
(-0.29%) $0.798
(1.16%) $92.94
@ $4.78
发出时间: 15 Feb 2024 @ 01:00
回报率: -22.38%
上一信号: Feb 13 - 23:49
上一信号:
回报率: -0.46 %
Live Chart Being Loaded With Signals
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering...
Stats | |
---|---|
今日成交量 | 340 219 |
平均成交量 | 563 159 |
市值 | 386.32M |
EPS | $0 ( 2024-03-12 ) |
下一个收益日期 | ( $-0.140 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.03 |
ATR14 | $0.00200 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Johnston John Joseph | Buy | 5 000 | Common Stock |
2024-03-26 | Johnston John Joseph | Sell | 5 000 | Common Stock |
2024-03-26 | Johnston John Joseph | Sell | 5 000 | Stock Option (right to buy) |
2024-03-15 | Ross Thomas M. | Buy | 100 000 | Employee Stock Option (right to buy) |
2024-03-15 | Ross Thomas M. | Buy | 25 000 | Common Stock |
INSIDER POWER |
---|
40.18 |
Last 100 transactions |
Buy: 1 609 082 | Sell: 743 053 |
音量 相关性
MaxCyte, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
MaxCyte, Inc. 相关性 - 货币/商品
MaxCyte, Inc. 财务报表
Annual | 2023 |
营收: | $41.29M |
毛利润: | $32.56M (78.86 %) |
EPS: | $-0.370 |
FY | 2023 |
营收: | $41.29M |
毛利润: | $32.56M (78.86 %) |
EPS: | $-0.370 |
FY | 2022 |
营收: | $44.26M |
毛利润: | $39.16M (88.48 %) |
EPS: | $-0.190 |
FY | 2021 |
营收: | $33.89M |
毛利润: | $30.25M (89.24 %) |
EPS: | $-0.210 |
Financial Reports:
No articles found.
MaxCyte, Inc.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。